Locatelli, F., Zugmaier, G., Rizzari, C., Morris, J., Gruhn, B., Klingebiel, T., et al. (2023). Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL. LEUKEMIA, 37(1), 222-225 [10.1038/s41375-022-01770-3].

Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL

Rizzari C.;
2023

Lettera in rivista
Antibodies, Bispecific; Child; Disease-Free Survival; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction
English
8-dic-2022
2023
37
1
222
225
open
Locatelli, F., Zugmaier, G., Rizzari, C., Morris, J., Gruhn, B., Klingebiel, T., et al. (2023). Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL. LEUKEMIA, 37(1), 222-225 [10.1038/s41375-022-01770-3].
File in questo prodotto:
File Dimensione Formato  
unpaywall-bitstream--1882860887.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Creative Commons
Dimensione 709.61 kB
Formato Adobe PDF
709.61 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/427802
Citazioni
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 10
Social impact